Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.GRAY · Entity 7804 | Chief Medical Officer | March 23, 2023 | March 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date March 23, 2023 · Filed March 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,982 |
Last balance in matching sequence
After 2023-03-23 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-23 · Disposition to issuer · Acquired 42,771 · Balance 46,883 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F2: Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. Row 2 · 2023-03-23 · Tax withholding · Disposed 17,901 · Balance 28,982 F2: Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-23 · Disposition to issuer · Disposed 42,771 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
F2: Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2023 Filed Mar 27, 2023 23:59 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Disposition to issuerRestricted Stock Unit · Derivative | 42,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-021307 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,771 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 23:59 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 17,901 | $5.50 | $98,455.50 |
DisclosureSEC source: 0001209191-23-021307 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,982 F2 · balance_after: Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 23:59 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Disposition to issuerCommon Stock | 42,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-021307 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,883 F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F2 · balance_after: Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 5 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,750 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Unit · Derivative | 83,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 4 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,375 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 42,894 | $0.57 | $24,449.58 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,338 Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionCommon Stock | 120,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:50 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059206 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:50 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 2,752 | $0.63 | $1,733.76 |
DisclosureSEC source: 0001209191-22-059206 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,577 Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:50 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-059206 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 24, 2022 Filed Nov 29, 2022 21:37 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Units · Derivative | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058950 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,875 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| November 24, 2022 Filed Nov 29, 2022 21:37 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 8,255 | $0.67 | $5,530.85 |
DisclosureSEC source: 0001209191-22-058950 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,954 Read SEC document |
| November 24, 2022 Filed Nov 29, 2022 21:37 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionCommon Stock | 28,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058950 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:49 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantRestricted Stock Units · Derivative | 450,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047723 · doc4.xml · derivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:16 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047231 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,125 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:16 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 2,668 | $0.97 | $2,587.96 |
DisclosureSEC source: 0001209191-22-047231 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,084 Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:16 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-047231 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:47 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031350 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:47 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Tax withholdingCommon Stock | 13,123 | $0.90 | $11,825.14 |
DisclosureSEC source: 0001209191-22-031350 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,377 Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:47 UTC | CalciMedica, Inc. GRAY · Entity 7804 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031350 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:58 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantRestricted Stock Unit · Derivative | 83,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015052 · doc4.xml · derivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,155 Underlying: Common Stock · 83,155 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. F3 · derivative.expiration_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:58 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 63,845 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001209191-22-015052 · doc4.xml · derivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,845 Underlying: Common Stock · 63,845 shares Expires 2032-02-27 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:23 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034909 · doc4.xml · derivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:23 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 219,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001209191-21-034909 · doc4.xml · derivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,000 Underlying: Common Stock · 219,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: The stock option vests as to 1/4 of the total shares on May 19, 2022 and then 1/48 of the total shares monthly until the option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:11 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $23.66 | $0.00 |
DisclosureSEC source: 0001209191-20-062756 · doc4.xml · derivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-07 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.